EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

ROS-mediated senescence and autophagy inhibition drive 5-FU/Aumolertinib synergy in colorectal cancer

Peipei Liu, Xiao Wu, Zuojie Jiang, Pei Zhang, Zixuan Meng, Chenming Xu, Di Ao, Jing Jiang, Hao Liu

European Journal of Pharmacology · 2026-01 · 1011 · 178448

DOI: 10.1016/j.ejphar.2025.178448 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Pharmacology, 2026-01. Verfasst von Peipei Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Bengbu Medical University, Bengbu, China; Department of Pediatrics, First Affiliated Hospital of Bengbu Medical University, Bengb…. Hauptthemen laut MEDLINE: Reactive Oxygen Species, Fluorouracil, Autophagy, Colorectal Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Anhui Province Excellent Young Talents Fund Program of Higher Education Institutions.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epidermal growth factor receptor (EGFR) is frequently overexpressed in colorectal cancer (CRC) and promotes tumor invasion and metastasis. Although 5-fluorouracil (5-FU) serves as a first-line CRC therapeutic, its clinical utility is constrained by dose-dependent toxicity. This study demonstrated that combining 5-FU with the EGFR inhibitor aumolertinib (AUM) synergistically suppressed CRC progression while reducing effective 5-FU doses. Transcriptomic and functional analyses linked this synergy to cellular senescence and autophagic flux blockade. Mechanistically, reactive oxygen species (ROS) accumulation drives senescence and autophagy inhibition, which inactivates the PI3K/AKT/mTOR pathway, thereby inhibiting CRC cell proliferation, invasion, and migration. Notably, ROS scavenging with N-acetylcysteine reversed these effects. The synergistic tumor growth inhibition was confirmed in HCT116 xenografts using low-dose combination therapy (5-FU 15 mg/kg + AUM 10 mg/kg). Collectively, these findings establish an ROS-dependent autophagic senescence axis as the molecular basis for 5-FU/AUM synergy, offering a novel strategic approach for CRC treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Reactive Oxygen SpeciesFluorouracilAutophagyColorectal NeoplasmsCellular SenescenceAcrylamidesAntineoplastic Combined Chemotherapy ProtocolsHumansAnimalsDrug SynergismMiceHCT116 CellsXenograft Model Antitumor AssaysCell ProliferationErbB ReceptorsMice, NudeSignal TransductionCell MovementProto-Oncogene Proteins c-akt

Stichwörter der Autor:innen

5-FluorouracilAumolertinibAutophagy-senescence axisColorectal cancerSynergistic effect

Substanzen

Reactive Oxygen SpeciesFluorouracilAcrylamidesErbB ReceptorsProto-Oncogene Proteins c-akt

Autor:innen und Institutionen

  • School of Pharmacy, Bengbu Medical University, Bengbu, China; Department of Pediatrics, First Affiliated Hospital of Bengbu Medical University, Bengbu, China.
  • Chemotherapy Department of the First Affiliated Hospital of Bengbu Medical University, Bengbu, China.
  • School of Pharmacy, Bengbu Medical University, Bengbu, China.
  • School of Pharmacy, Bengbu Medical University, Bengbu, China; Anhui Province Engineering Technology Research Center of Biochemical Pharmaceutical, Bengbu, China.
  • Department of Gastroenterology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, China.
  • Emergency Surgery Department of the First Affiliated Hospital of Bengbu Medical University, Bengbu, China. Electronic address: 13855208940@163.com.

Förderung

  • Anhui Province Excellent Young Talents Fund Program of Higher Education Institutions

Zitieren

APA

Liu, P., Wu, X., Jiang, Z., Zhang, P., Meng, Z., Xu, C., Ao, D., Jiang, J., & Liu, H. (2026). ROS-mediated senescence and autophagy inhibition drive 5-FU/Aumolertinib synergy in colorectal cancer. European Journal of Pharmacology, 1011, 178448. https://doi.org/10.1016/j.ejphar.2025.178448

Vancouver

Liu P, Wu X, Jiang Z, Zhang P, Meng Z, Xu C, et al. ROS-mediated senescence and autophagy inhibition drive 5-FU/Aumolertinib synergy in colorectal cancer. European Journal of Pharmacology. 2026;1011:178448. doi:10.1016/j.ejphar.2025.178448

BibTeX
@article{Liu2026,
  author = {Liu, Peipei and Wu, Xiao and Jiang, Zuojie and Zhang, Pei and Meng, Zixuan and Xu, Chenming and Ao, Di and Jiang, Jing and Liu, Hao},
  title = {ROS-mediated senescence and autophagy inhibition drive 5-FU/Aumolertinib synergy in colorectal cancer},
  journal = {European Journal of Pharmacology},
  year = {2026},
  volume = {1011},
  pages = {178448},
  doi = {10.1016/j.ejphar.2025.178448}
}
Kostenlos starten →